2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 119

Targeting Dysregulated CD38/NAD+ Homeostasis Mitigates Multiple Organ Fibrosis
Abstract Number: 2965

Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation
Abstract Number: 2084

Targeting the Voltage-Gated K+ Channels: T Cell Targeted Therapies for Spondyloarthritis
Abstract Number: 41

TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Improves Bone Strength in Mouse Model for Rheumatoid Arthritis
Abstract Number: 2211

Technetium Tc 99m Tilmanocept: A Targeted Immunodiagnostic Radiopharmaceutical for the Assessment of Synovial Macrophage Activity in Rheumatoid Arthritis
Abstract Number: 293

Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays
Abstract Number: 2169

Temporal Trends in Mortality in Patients Hospitalized for Cerebrovascular Events with Psoriatic Arthritis: Data from the Healthcare Cost and Utilization Project from 2010-2014
Abstract Number: 909

Temporal Trends of ANCA-Associated Vasculitis Comorbidities: Results from a National, Longitudinal, Matched-Cohort Study
Abstract Number: 2868

Tender Joint Count May Not Reflect Inflammatory Activity in Established Rheumatoid Arthritis Patients; Results from a Longitudinal Study of Tocilizumab
Abstract Number: 2239

Tenocytes Extracted from Rotator Cuff Tendons Are Able to Induce Mineral Deposition in Vitro and Express Genes Related to a Chondrocyte Differentiation
Abstract Number: 1039

Tenofovir Induces Osteopenia and Dipyridamole, an Inhibitor of the Ent-1 Nucleoside Transporter, Reverses the Osteopenic Effect of Tenofovir In Vivo
Abstract Number: 1038

Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine
Abstract Number: 1202

Tenosynovial Aspiration By Ultrasound Guidance: Even Small Volumes Can Have a Big Impact
Abstract Number: 1203

Tenosynovitis Detected By Ultrasound Predicts Arthritis Onset in Individuals at Risk of Developing Rheumatoid Arthritis
Abstract Number: 307

Tenosynovitis on MRI of Bilateral Hands and Its Concordance with Joint Swelling/Tenderness in Patients with Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].